R&D software firm Accelrys says it will speed up the pharma QA/QC process and reduce the compliance risk ten-fold through its $35m takeover of VelQuest.
The US Food and Drug Administration (FDA) will soon start asking drugmakers to play a greater role in guideline development. Before that process begins in-Pharmatechnologist.com takes a look at the documents published by the agency in 2011.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
Frontage Laboratories has teamed up with Janssen Pharmaceuticals to develop a chromatographic preclinical testing method they say could finally solve metformin development issues.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
ADC Biotechnology (ADC Bio) has secured a development grant for a new antibody drug conjugate (ADC) manufacturing technology that, it says, can make drug production cheaper.
Outsourcing-Pharma presents its weekly round-up of the latest movers and shakers in the pharmaceutical industry, including news from Inviragen, Auxilium, and Icon Biosciences.
In September Outsourcing-pharma held Patient Recruitment Outsourcing (PRO) in Boston, bringing together the movers and shakers in the recruitment sector. Robert Loll, vice president of business development, shares his thoughts on the event with a particular...
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
in-PharmaTechnologist presents its round-up of the latest career moves within the world of pharmaceuticals, including news from AstraZeneca, Apricus, and BioTime.
Chemicals supplier Lonza will manufacture the API for a candidate Alzheimer’s disease drug being developed by Elan in an agreement announced yesterday.
in-PharmaTechnologist presents its round-up of the latest drug delivery research developments in the pharmaceutical world, including tumour targeting peptides and lipid nanoparticle drug-delivery technology.
in-PharmaTechnologist presents its weekly line-up of the latest appointments in the pharmaceutical industry, including news from Genesis, Acino and Pharmalink AB.
The CRO industry is still considered a good long-term investment and the clinical services segment is set to continue its dominance thanks to sponsor R&D spending, says leading banker.
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Piramal Healthcare has added commercial-scale antibody-drug-conjugate (ADC) manufacturing capacity at its UK plant predicting increasing demand for this specialist type of contracting.
in-PharmaTechnologist presents its round-up of the latest appointments in the pharmaceutical industry, including news from BIO, Natrix, Amarantus and 3M.
Retrofitting stainless steel plants with single-use systems is driving a “paradigm shift” in drug production but creates logistical problems, an AAPS panel said.
3M, the US-headquartered multinational, has launched a new range of bio filters which it says raise the benchmarks for flow-rate, organism reduction and efficiency across a range of applications.
in-PharmaTechnologist presents its round-up of the latest appointments within the pharmaceutical industry, including news from Novocure, YM BioSciences, and SGVI.
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
